Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
3
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
1 competitor in Traumatic Brain Injury
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Melatonin Neurim
Melatonin Neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
View on EMASlenyto
Slenyto is indicated for: treatment of insomnia in children and adolescents aged 2-18 years with Autism Spectrum Disorder (ASD), and / or neurogenetic disorders with aberrant diurnal melatonin secretion and /or nocturnal awakenings, where sleep hygiene measures have been insufficient. treatment of insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been insufficient.
View on EMACircadin
Circadin is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
View on EMA